ANTIVIRAL THERAPY

metrics 2024

Elevating knowledge in the fight against viruses.

Introduction

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

Metrics 2024

SCIMAGO Journal Rank0.45
Journal Impact Factor1.30
Journal Impact Factor (5 years)1.50
H-Index93
Journal IF Without Self1.30
Eigen Factor0.00
Normal Eigen Factor0.20
Influence0.45
Immediacy Index0.60
Cited Half Life11.10
Citing Half Life6.60
JCI0.22
Total Documents2366
WOS Total Citations1736
SCIMAGO Total Citations22134
SCIMAGO SELF Citations1137
Scopus Journal Rank0.45
Cites / Document (2 Years)1.45
Cites / Document (3 Years)1.47
Cites / Document (4 Years)1.41

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #165/272
Percentile 39.34
Quartile Q3
Infectious Diseases in Medicine
Rank #211/344
Percentile 38.66
Quartile Q3
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #219/313
Percentile 30.03
Quartile Q3

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 112/132
Percentile 15.50
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 283/354
Percentile 20.20
Quartile Q4
VIROLOGY
Rank 37/41
Percentile 11.00
Quartile Q4

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 116/132
Percentile 12.12
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 309/354
Percentile 12.71
Quartile Q4
VIROLOGY
Rank 39/41
Percentile 4.88
Quartile Q4

Quartile History

Similar Journals

JOURNAL DE MYCOLOGIE MEDICALE

Bridging Mycology and Clinical Practice
Publisher: MASSON EDITEURISSN: 1156-5233Frequency: 4 issues/year

JOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.

ANTI-CANCER DRUGS

Empowering Researchers in the Fight Against Cancer
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Annual Review of Virology

Advancing virology through comprehensive insights.
Publisher: ANNUAL REVIEWSISSN: 2327-056XFrequency: 1 issue/year

Annual Review of Virology is a premier scholarly journal published by Annual Reviews, dedicated to advancing the field of virology through comprehensive and insightful reviews. Since its inception in 2014, this journal has established itself as a leading resource for researchers, professionals, and students alike, achieving an impressive Q1 ranking in the field of Virology and a Scopus rank of #10 out of 80 in its category, placing it in the 88th percentile. The journal features in-depth analyses of the latest developments in virology, encompassing various aspects such as viral pathogenesis, host interactions, and antiviral strategies, thereby catering to a diverse audience seeking the most relevant and cutting-edge information. Although it is not Open Access, Annual Review of Virology remains an indispensable tool for those engaged in virology research, transforming complex findings into accessible knowledge that shapes future investigations and practical applications in the field.

ACTA VIROLOGICA

Pioneering knowledge in viral diagnostics and treatment.
Publisher: FRONTIERS MEDIA SAISSN: 0001-723XFrequency: 4 issues/year

ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.

ARCHIVES OF VIROLOGY

Pioneering insights into virology's challenges.
Publisher: SPRINGER WIENISSN: 0304-8608Frequency: 12 issues/year

Archives of Virology is a prestigious academic journal dedicated to the field of virology, published by Springer Wien. Established in 1975, this journal has been a crucial platform for disseminating innovative research findings and advancements in the understanding of viral diseases and their impact on human health. It holds a notable position in the academic landscape, with a 2023 impact factor placing it in Q2 within the field of Medicine (miscellaneous) and Q3 in Virology. Its Scopus ranking within the Virology category further underscores its relevance, with a notable percentile of 45th. Although it does not provide Open Access options, the journal's rigorous peer-review process ensures the highest quality of published work, making it an essential resource for researchers, professionals, and students aiming to stay updated in the rapidly evolving field of virology. For those committed to advancing their understanding of viruses and viral diseases, Archives of Virology is a vital scholarly resource.

Advances in Virology

Pioneering Insights in Virology Research
Publisher: HINDAWI LTDISSN: 1687-8639Frequency: 1 issue/year

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

ADVANCES IN THERAPY

Unveiling the future of medicine through rigorous research.
Publisher: SPRINGERISSN: 0741-238XFrequency: 12 issues/year

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

ANTIVIRAL RESEARCH

Transforming Understanding of Viral Challenges
Publisher: ELSEVIERISSN: 0166-3542Frequency: 12 issues/year

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Empowering healthcare through innovative pharmacological research.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Microbiology Spectrum

Fostering collaboration through open access innovation.
Publisher: AMER SOC MICROBIOLOGYISSN: 2165-0497Frequency: 6 issues/year

Microbiology Spectrum is a prominent peer-reviewed journal published by the American Society for Microbiology, dedicated to advancing the field of microbiology through the dissemination of high-quality research. Since its inception in 2013 and continuing until 2024, the journal has established a strong presence in key domains such as microbiology, immunology, cell biology, and ecology, achieving impressive quartile rankings including Q1 in Infectious Diseases and Q1 in Immunology and Microbiology as of 2023. With an emphasis on open access to its scholarly content, Microbiology Spectrum aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike. The journal's scope encompasses a diverse range of topics pertinent to the field, making it an essential resource for anyone involved in microbiological research and its applications. Researchers looking to publish their findings in a respected journal will find Microbiology Spectrum's robust impact factor and Scopus rankings serve as testament to its significance and influence within the academic community.